11/18
08:22 am
thar
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease [Yahoo! Finance]
High
Report
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease [Yahoo! Finance]
11/18
08:00 am
thar
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Medium
Report
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
11/13
08:00 am
thar
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
High
Report
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
11/4
09:00 am
thar
Tharimmune Announces Upcoming Conference Presentations
High
Report
Tharimmune Announces Upcoming Conference Presentations
10/30
08:00 am
thar
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
High
Report
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
10/28
09:00 am
thar
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Medium
Report
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
10/25
08:00 am
thar
Tharimmune Announces Upcoming Conference Presentations
Medium
Report
Tharimmune Announces Upcoming Conference Presentations
9/30
07:00 am
thar
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
High
Report
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
9/16
07:00 am
thar
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Low
Report
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab